
The European zzso Agency zzso is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union zzso Since 2005, the agency has become responsible for the approval of all new zzso drugs in the zzso In this article we describe the mission, role, and responsibilities of the zzso and provide a brief summary of recent initiatives related to cancer drug zzso The zzso recently published its Road zzso to zzso Over the next 5 years, the agency aims to continue to stimulate drug development in areas of zzso medical zzso zzso drug safety, one of the priorities over the next few years will be to establish a more proactive approach in ensuring patient zzso This is the result of new zzso legislation coming into force in 2012 that will strengthen the way the safety of medicines for human use is monitored in the zzso In terms of its general operation, the agency is committed to increased openness and zzso and to build on its interactions with zzso including members of academia, health care professionals, patients, and health technology assessment zzso The agency recently created an zzso working party to expand the current zzso for the development and evaluation of cancer zzso The zzso focuses on both exploratory and zzso studies for different types of zzso The current revision will address a number of topics, including the use of zzso as an integrated part of drug development and the use of zzso survival as a primary zzso in registration zzso 

